RFA-IP-24-045: Network of Community Cohorts for Monitoring Changes in Respiratory Virus Epidemiology (Pandemic Preparedness Cohorts)
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2023.
Centers for Disease Control and Prevention - ERA offered grants of up to $5.8 million (at least $937,500) to nonprofits, colleges and universities, state and local governments, tribes and businesses. It expected to make about 9 awards worth $95.3 million in total. Applications closed on February 20, 2024.
From the official notice on Grants.gov, last changed December 14, 2023. Checked November 7, 2026.
- Award ceiling$5.8 million
- Award floor$937,500
- Total funding$95.3 million
- Expected awards9
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 14, 2023 |
|---|---|
| Deadline | February 20, 2024 |
| Archived by Grants.gov | March 21, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes and businesses.
All 13 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases awards averaged $1.9 million; this notice allows up to $5.8 million per award.
- Most of the program's money (84% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
At the start of the COVID-19 pandemic, infrastructure for understanding the epidemiology of a rapidly evolving virus in real-time was limited. Given the long lead time required for the government to start new projects, the CDC harnessed a variety of studies and platforms designed for other purposes to begin collecting the specimen and survey data needed to understand COVID-19 risk, burden, severity, and immunity. While hospital-based platforms were key to understanding frequency and risk factors for severe disease, community-based platforms were important for understanding viral kinetics, risk factors for infection, transmission dynamics, long-term outcomes, and the impact of vaccination on each of these measures. This funding opportunity would build on the lessons learned during the COVID-19 pandemic and establish a network of community-based cohorts, including diverse age groups (target populations: younger than 5 years old, 5-17 years old, 18-64 years old, and older than 64 years old), demographic characteristics, and regions in the US, to allow ongoing monitoring of changes in respiratory virus epidemiology in the years following the COVID-19 pandemic. A consolidated network will be more efficient and cost savings than current disparate mechanism, strengthen communication/collaboration, and enhance CDC's preparedness to quickly obtain data on infection risk, transmission, and effectiveness of preventive measures in response to a novel virus or variant.
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases (93.083) awarded $58.2 million across 30 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Council of Medical Specia | Illinois | 1 | $40.4 million |
| Post-Acute and Long-Term Care Medical Association, Inc. | Maryland | 1 | $7.1 million |
| National Health Laboratory Service | 1 | $3.1 million | |
| All India Institute of Medical Sciences | 1 | $1.0 million | |
| American Cancer Society, Inc | Georgia | 2 | $900,000 |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-IP-24-045 still open?
No. It closed on February 20, 2024. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Network of Community Cohorts for Monitoring Changes in Respiratory Virus Epidemiology (Pandemic Preparedness Cohorts)?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes and businesses.
What is the deadline for Network of Community Cohorts for Monitoring Changes in Respiratory Virus Epidemiology (Pandemic Preparedness Cohorts)?
Closed February 20, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $5.8 million each. About $95.3 million in total across about 9 awards.
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before?
The largest recipients over five fiscal years were Council of Medical Specia, Post-Acute and Long-Term Care Medical Association, Inc., National Health Laboratory Service. The program made 30 awards worth $58.2 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)